Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with one of the following advanced or spreading cancers: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), endometrial cancer, or triple negative breast cancer (a specific type of breast cancer that tests negative for certain receptors).
• People who have already received all standard treatments considered appropriate for them by their doctor, or for whom no standard treatment is available, or who have chosen not to continue with remaining standard treatment options.
• People with a general health and activity level rated at 0 or 1 on a standard medical scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site).
• For certain parts of the trial (Cohort A2, Cohort B/C): People who have at least one area of cancer that can be measured on a scan using standard criteria.
• For specific lung cancer groups (Cohorts B1/B2): People with non-small cell lung cancer that does not have certain known genetic changes, and who have received no more than 2 prior treatment courses for advanced disease (in the safety phase), or no prior treatment for advanced disease (in the expansion phase).

Who may not be able to join:

• People who have previously been treated with a specific type of targeted drug (a PTK7 antibody-drug conjugate that uses a topoisomerase I inhibitor) — note that some other similar drugs may still be permitted (confirm with trial site).
• People who still have significant unresolved side effects from a previous cancer treatment.
• People with a known or suspected history of uncontrolled cancer that has spread to the brain or spinal cord.
• People with an active, uncontrolled infection (bacterial, viral, fungal, or parasitic).
• People with serious heart or cardiovascular disease.
• People whose heart electrical activity shows a specific abnormality on a heart tracing (ECG) beyond a certain threshold (confirm with trial site).
• People with a history of lung inflammation or scarring of the lung tissue (a condition called pneumonitis or interstitial lung disease).
• People who are currently pregnant, breastfeeding, or planning to breastfeed during the trial or within 30 days of the last dose of the trial treatment.

Important: Always verify eligibility with the trial site directly before applying.